The largest database of trusted experimental protocols

5 protocols using cd25 pe cf594

1

Comprehensive Immunophenotyping of Peripheral Blood

Check if the same lab product or an alternative is used in the 5 most similar protocols
PB samples were collected through venipuncture in 2 mL BD Vacutainer® spray-coated K2EDTA blood collection tubes (BD Biosciences, San Jose, CA, USA; #367841). One hundred μL of whole blood was transported into 5 mL Corning™ Falcon™ Round-Bottom Polystyrene Tubes (#352054) and stained with 12 monoclonal antibodies against the surface markers: CD45-APC-H7 (clone 2D1, #560178); CD3-PerCP (clone SK7, #340663); CD4-BV510 (clone SK3; #562970); CD8-PE (clone HIT8a, #555635); CD14-BV605 (clone M5E2, #564054); CD16-APC (clone B73.1, #561304); CD56-APC-R700 (clone NCAM16.2, #565139); CD25-PE-CF594 (clone M-A25, #562403); CD11b-BV786 (clone D12, #742642); CD183 (CXCR3)-BV421 (clone 1C6/CXCR3, #562558); CD194 (CCR4)-BV650 (clone 1G1, #744140); and CD196 (CCR6)-BB515 (clone 11A9, #564479) (all from BD Biosciences). The staining procedure was performed in BD Horizon™ Brilliant Stain Buffer (BD Biosciences, #563794) followed by red blood cells lysis with 1x BD FACS™ lysing solution (BD Biosciences, #349202) as suggested by the manufacturer for the Lyse-no-Wash protocol.
+ Open protocol
+ Expand
2

Comprehensive Immunophenotyping of CLL Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols
PBMCs from each CLL donor were fixed, barcoded,34 and stained for 30 min with the antibody panel. The following antibodies were used: CD3-BUV395, CD4-BUV563, HLA-DR-BUV615, CD16-BUV737, CXCR5 (CD185)-BUV805, CCR7 (CD197)-BV605, CCR6 (CD196)-BV711, CD56-BV750, CD127-BV786, PD-1 (CD279)-BB700, CD14-PE, CD25-PE-CF594, CCR3 (CD183)-PE-Cy5, CD45RA-PE-Cy7, CD69-APC-R700, CD8/CD19-APC-Cy7 (BD Biosciences). Experiments were analyzed with a BD FACSymphony A5 cytometer (BD Biosciences) and further processed in Cytobank (https://cellmass.cytobank.org/cytobank/). The FlowSOM clustering algorithm was applied to identify cell populations, which were validated by manual gating. The UMAP dimensionality reduction algorithm was used to visualize the data.
+ Open protocol
+ Expand
3

Immunotherapy for Prostate Cancer in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Six-week-old FVB/NJ mice were implanted with 1×106 MyC-CaP cells administered subcutaneously. Only male mice were used for these studies, given that the tumor of origin is male specific. Each mouse was then immunized intradermally with 100 μg DNA vaccine (pTVG-AR), or vector control (pTVG-4) weekly, beginning 1 day after tumor implantation. TLR agonists were coadministered with the vaccine intradermally at the following doses: TLR3 (Poly(I:C) HMW, 100 µg/mouse), TLR9 (ODN 1826, 50 µg/mouse). Mice were further treated with immune checkpoint blockade, αPD-1, αLAG-3, αCTLA-4, or IgG control the day following each immunization. Tumor volumes were measured as described above. In a parallel study, tumors were collected after treatment and digested in collagenase, DNAse I, and protease inhibitors for 2 hours at 37°C, passed through a 100 mm mesh screen, and analyzed by flow cytometry with the following antibodies: CD3-FITC (BD 555274), CD4-BUV395 (BD 563790), CD8-BV785 (BD 563332), CD25-PE-CF594 (BD 562694), CD44-PE-Cy7 (BD 561283), CD45-BV510 (BD 563891), CD62L-BV605 (BD 563252), CD127-APC (Biolegend 121122), KLRG1-BV711 (BD 564014), FOXP3-PE (Thermo Fisher 12-5773-82), 4-1BB-PerCP-eF710 (Lifetech 46-1371-82), and Live/Dead Ghost dye 780 (Tonbo, San Diego, CA 13-0865-T100).
+ Open protocol
+ Expand
4

Isolation and Flow Cytometry Analysis of Leukocytes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Leukocytes from lymph nodes, blood, spleen and peritoneal cavity wash were collected and isolated as described [56 (link)], and analysed by flow cytometry. Anti-mouse CD16/CD32 antibody (1:50, BD Biosciences, clone #2.4G2) was used to block non-specific binding. The following fluorochrome-conjugated antibodies were used: CD3e-AF700 (1:200, BD Biosciences, clone #500A2), CD4-BUV395 (1:100, BD Biosciences, clone #RM4-5), CD8a-PerCP (1:100, BioLegend, clone #53-6.7), CD25-PE-CF594 (1:100, BD Biosciences, #PC-61), FoxP3-APC (1:50, eBioscience, clone #FJK-16S), CD11b-APC (1:200, BioLegend, clone #MI/71), CD11c-BV421 (1:50, BD Bioscience, clone #HL3), GR1-PerCP Cy5.5 (1:200, BD Biosciences, clone #RB6-8C5), F4/80-BV711 (1:100, BioLegend, clone #BM8) and MHCII-APC/Cy7 (1:500, BioLegend, clone #M5/114.15.2). Single-stained beads were used to set compensation controls, and fluorescence-minus-one (FMO) controls were used to define population gates. Data were acquired using a BD LSRFortessa X-20 (BD Biosciences), and were analysed using FlowJo software v10.5.0 (BD Biosciences).
+ Open protocol
+ Expand
5

Phenotyping Human PBMC Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Single-cell suspensions from human PBMCs, prepared as below, were washed in flow cytometry staining buffer (PBS with 2% FCS and 0.02% sodium azide) followed by blocking with 10% FCS. The following mAbs from BD Biosciences were used at optimally titrated concentrations: CD1d-allophycocyanin (51.1), CD5-V450 (UCHT2), CD19-FITC (HIB19), CD24-PerCP-Cy5.5 (ML5), CD25-PE-CF594 (M-A251), CD27-V500 (M-T271), CD38-AF700 (HIT2). Viable cells were distinguished using Fixable Viability Dye eFluor R 780 (eBioscience).
Populations of interest were gated as above. Representative gating strategy is illustrated in Supporting Information Figure 2. Samples were acquired on an LSR Fortessa flow cytometer (BD Biosciences) and were analyzed with FlowJo software (Tree Star).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!